Curis, Inc.

Primary central nervous system lymphoma (PCNSL) is a rare, invasive form of non-Hodgkin lymphoma with significant challenges in diagnosis and treatment. Experts offer valuable perspectives on treatment approaches and strategies for navigating this disease. bloodcancerstoday.com/post/what-do-t…

Curis is thrilled to participate in ASH! We're eager to connect with our dedicated investigators, share updates, and collaborate with leaders in Primary CNS Lymphoma treatment. Stop by Booth #2605 to learn more about our contributions to advancing care and research in hematology.

We are delighted by the ongoing success of the International Academy for Clinical Hematology in delivering exceptional educational content. Their recent journal club on Primary CNS Lymphoma (pCNSL) was no exception. youtu.be/gg562Yf803w

Grzegorz S. Nowakowski, MD, discusses the potential implications of the TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with PCNSL. onclive.com/view/dr-nowako… via @onclive

We’re excited to share the latest advancements on emavusertib (CA-4948) from our 3rd Annual #IRAK-4 in #Cancer Symposium! Catch up on the insightful presentations and new data shared by our expert speakers through the link below. #TakeAim #Emavusertib curis.com/resources/

Don't miss your chance to register for the 3rd Annual Symposium on #IRAK4 in #Cancer, happening virtually on Thursday, September 26, 2024. We’re excited to share updated data from 10 evaluable patients in Curis’s PCNSL study. Register now: cvent.me/kDaoDK

Grzegorz S. Nowakowski, MD, discusses synergy between IRAK4 and BTK inhibitors and its potential implications for tumors refractory to BTK inhibitor treatment.onclive.com/view/takeaim-l… via @onclive

Announcing the 3rd Annual #IRAK4 Symposium, occurring virtually on Thursday, Sept. 26, 2024, from 9am to 1pm ET. Save your spot to learn about the biology of IRAK4 and its emerging clinical role as a target in the treatment of hematologic malignancies and other cancers.

We're excited to share new data from the TakeAim studies of emavusertib in lymphoma and leukemia at the @ASCO Annual Meeting #ASCO2024! If you're attending, please visit our booth (Booth 21156) and our posters; see info below #CRIS #emavusertib

Exciting developments in the fight against Primary Central Nervous System Lymphoma. New targeted therapies show promise in tackling its mechanisms, including B-cell receptor and toll-like receptor pathways. tandfonline.com/doi/full/10.10…

Dr. Cerchione discusses emavusertib (CA-4948) plus azacitidine and venetoclax as a triplet regimen in patients with acute myeloid leukemia (AML) in complete response with measurable residual disease (MRD). #AACR2024 bloodcancerstoday.com/post/claudio-c…

Eric Winer, MD, Clinical Dir., Leukemia at DFCI, notes progress of TakeAim study, "It's terrific to see results of emavusertib; what’s nice about emavusertib is it seems to work in patients with FLT3 mutations, but also in those who have previously received FLT3 inhibitors."

Dr. Mims, oncologist and associate professor at The Ohio State University Comprehensive Cancer Center, explores the potential of emavusertib, an IRAK4 and FLT3 inhibitor, in pretreated patients with FLT3-mutated relapsed or refractory AML or MDS. lnkd.in/dpdNT5bH

Grzegorz S. Nowakowski, MD, discusses findings from the ongoing phase 1/2 TakeAim Lymphoma trial of emavusertib in combination with ibrutinib in patients with relapsed/refractory hematologic malignancies. onclive.com/view/dr-nowako… 📷

Thrilled to share our progress in leukemia and lymphoma studies at the 65th ASH Annual Meeting with 3 presentations! Join us at booth #2107 to meet the team. 🌟 #ASH23 #emavusertib #IRAK4 investors.curis.com/2023-12-06-Cur…

New article delves into the crucial role of the TLR signaling pathway in B-cell and myeloid malignancies. Emavusertib, an IRAK-4 inhibitor, is emerging as a promising treatment, showing efficacy in B-cell NHL and myeloid cancers. frontiersin.org/articles/10.33…

Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer. To learn more about this free-to-attend scientific event and register, please follow the link below. investors.curis.com/2023-09-12-Cur… $CRIS #oncology #hematology #drugdevelopment #clinicaltrials #relentless

Join @CurisInc for the 2nd annual symposium on #IRAK4 in #cancer, occurring virtually on Friday September 22, 2023, 9am–1pm ET. To learn about this promising target in the treatment of hematologic & other cancers, register here: cvent.me/YWvRDD #hematology #IRAK4Symposium

The FDA Removes Partial Clinical Hold on TakeAim Leukemia Study, RP2D Established at 300 mg BID. Read more here: investors.curis.com/2023-07-06-FDA…